Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel

Area of Science:

• Hematology
• Genomics
• Molecular Diagnostics

Background:

• Genomic understanding of lymphomas has rapidly advanced, influencing diagnosis and treatment.
• Current classifications emphasize genetic assessment for lymphoid neoplasms.
• There is a clinical need for accessible and rapid genetic testing.

Purpose of the Study:

• To clinically validate the Ion AmpliSeq Liverpool Lymphoid Network Panel (IALLNP) for genetic analysis of lymphomas.
• To assess the performance of the IALLNP on the Ion Torrent Genexus Sequencer.

Main Methods:

• Clinical validation of the IALLNP using 54 DNA samples and a commercial control.
• The panel targets single-nucleotide variants (SNVs) and insertions/deletions (indels) in 60 genes.
• Optimization for coverage, artifacts, and false-negative calls was performed.

Main Results:

• The IALLNP demonstrated high performance in coverage, on-target reads, and uniformity.
• Sensitivity and specificity for SNVs and indels were 100% at a 5% variant allele frequency (VAF).
• Reproducibility was 92.8%, with non-reproducible variants below the analytical threshold.

Conclusions:

• The IALLNP is an accurate and reproducible next-generation sequencing panel.
• It provides clinically relevant genetic information for lymphoid neoplasms.
• The panel offers results within a clinically meaningful timeframe.